zPREDICTA :
Resources :
Posters & Publications

Posters & Publications

Featured:

zpredicta-poster-1

Biology Reconstructed: Testing Immuno-Oncology Agents In Tumor-Specific 3D Cell Culture

Mukti R. Parikh and Julia Kirshner
AACR Virtual Annual Meeting 2020

Here we describe a tumor-specific 3D cell culture platform where the human tumor microenvironment is reconstructed ex vivo. Our 3D tumor-specific models incorporate tissue-specific extracellular matrix(ces) (ECM) and tumor-specific medium supplements allowing for a true reconstruction of tumor microenvironment. Our approach is compatible with multiple classes of immuno-oncology agents from naked antibodies and antibody-drug conjugates, to bi- and tri-specific compounds, and CAR-T cells.

zpredicta-poster-2

Reconstructed Bone (r-Bone): A Patient-Derived 3D Culture Platform For Prediction Of Clinical Outcomes In Multiple Myeloma

Amrita Krishnan, Nitya Nathwani, Michael Rosenzweig, Chatchada Karanes, Myo Htut, Sahebi Firoozeh, Steven Rosen, Julia Kirshner
AACR Virtual Annual Meeting 2020

In this study, we aimed to evaluate the capacity of the Reconstructed Bone (r-Bone) model to predict clinical outcomes in patients with multiple myeloma. r-Bone cultures correctly predicted the outcome of 19 out of 21 cases. This data demonstrate that the r-Bone system could be used for pipeline attrition management to select drug candidates with the highest probability of clinical success and can be developed into a prognostic tool for the selection of treatment regimen for patients with multiple myeloma.

 

Additional Posters & Presentations:

1α,25-Dihydroxyvitamin D Inhibits the Metastatic Capability of MCF10CA1a and MDA-MB-231 Cells in an In Vitro Model of Breast to Bone Metastasis.

Wilmanski T, Barnard A, Parikh MR, Kirshner J, Buhman K, Burgess J, Teegarden D
Nutrition and Cancer

2016 68(7):1202-9

A reconstructed metastasis model to recapitulate the metastatic spread in vitro.

Parikh MR, Minser KE, Rank LM, Glackin CA, Kirshner J
Biotechnology Journal

2014 9(9):1129-39

Differentiation of cancer cells in two-dimensional and three-dimensional breast cancer models by Raman spectroscopy.

Damayanti NP, Fang Y, Parikh MR, Craig AP, Kirshner J, Irudayaraj J
Journal of Biomedical Optics

2013 18(11):117008

Maytansinoid immunoconjugate IMGN901 is cytotoxic in a three-dimensional culture model of multiple myeloma.

Nierste BA, Gunn EJ, Whiteman KR, Lutz RJ, Kirshner J
American Journal of Blood Research

2016 18;6(1):6-18

The natural products parthenolide and andrographolide exhibit anti-cancer stem cell activity in multiple myeloma.

Gunn EJ, Williams JT, Huynh DT, Iannotti MJ, Han C, Barrios FJ, Kendall S, Glackin CA, Colby DA, Kirshner J
Leukemia & Lymphoma

2011 52(6):1085-97

In a patient with biclonal Waldenstrom macroglobulinemia only one clone expands in three-dimensional culture and includes putative cancer stem cells.

Kirshner J, Thulien KJ, Kriangkum J, Motz S, Belch AR, Pilarski LM
Leukemia & Lymphoma

2011 52(2):285-9

A unique three-dimensional model for evaluating the impact of therapy on multiple myeloma.

Kirshner J, Thulien KJ, Martin LD, Debes Marun C, Reiman T, Belch AR, Pilarski LM
Blood

2008 112(7):2935-45

Mutation analysis of the short cytoplasmic domain of the cell-cell adhesion molecule CEACAM1 identifies residues that orchestrate actin binding and lumen formation.

Chen CJ, Kirshner J, Sherman MA, Hu W, Nguyen T, Shively JE
Journal of Biological Chemistry

2007 282(8):5749-60

CEACAM1, a cell-cell adhesion molecule, directly associates with annexin II in a three-dimensional model of mammary morphogenesis.

Chen CJ, Kirshner J, Sherman MA, Hu W, Nguyen T, Shively JE
Journal of Biological Chemistry

2007 282(8):5749-60

CEACAM1-4S, a cell-cell adhesion molecule, mediates apoptosis and reverts mammary carcinoma cells to a normal morphogenic phenotype in a 3D culture.

Kirshner J, Chen CJ, Liu P, Huang J, Shively JE Proc
Proceedings of the National Academy of Sciences

2003 100(2):521-6

Lawrence J. DeLucas, Ph.D

SVP, OPERATIONS,
Predictive Oncology
President, Soluble Biotech
At Predictive Oncology

Dr. DeLucas is the Vice president of Operations for Predictive Oncology and President and co-founder of Soluble Biotech, Inc. DeLucas is currently working to complete development of GMP facilities at Soluble Biotech and at TumorGenesis. In addition, he oversees Soluble Biotech’s solubility and stability contracts for numerous pharmaceutical/biotech companies.

Before Predictive Oncology

From 1981-2016 Dr. DeLucas was a faculty member at the University of Alabama at Birmingham (UAB) where he served as a Professor in the School of Optometry, Senior Scientist and Director of the Comprehensive Cancer Center X-ray Shared Facility, and Director of the Center for Structural Biology. Dr. DeLucas received five degrees from UAB culminating in a Doctor of Optometry degree and a Ph.D. degree in Biochemistry. He also received honorary Doctor of Science degrees from The Ohio State University, Ferris State University, the State University of New York (SUNY), and the Illinois College of Optometry. He has published 164 peer-reviewed research articles in various scientific journals, co-authored and edited several books on protein crystal growth and membrane proteins and is a co-inventor on 43 patents involving protein crystal growth, novel biotechnologies and structure-based drug design. DeLucas was a payload specialist NASA astronaut and member of the 7-person crew of Space Shuttle Columbia for Mission “STS-50”, called the United States Microgravity Laboratory-1 (USML-1) Spacelab mission. Columbia launched on June 25, 1992, returning on July 9.  In 1994 and 1995, Dr. DeLucas served as the Chief Scientist for the International Space Station at NASA Headquarters in Washington, D.C. In 1999, Dr. DeLucas was recognized as one of the scientists who could shape the 21st century in an article published by “The Sunday Times” of London titled “The Brains Behind the 21st Century.”  In 2004, he was recognized as a Top Ten Finalist for the Entrepreneur of the Year award from the Birmingham Business Journal. 

“ Soluble Biotech is continually demonstrating to pharmaceutical and biotech companies the significant value of its novel HSC technology for optimizing protein therapeutic formulations to treat a variety of chronic and infectious diseases. ”

Education
  • Five degrees from Univ. of Alabama at Birmingham (UAB): B.S. Chemistry, M.S. Chemistry, B.S. Physiological Optics, O.D. Optometry, Ph.D Biochemistry

  • Published 164 peer-reviewed research articles in various scientific journals

  • 1993-2016: Director of the UAB Comprehensive Cancer Center X-ray Shared Facility, and Director of the Center for Structural Biology

  • NASA Astronaut, flew on Columbia Space Shuttle

  • 1994-1995: Appointed Chief Scientist for the International Space Station at NASA HQ
  • Arlette Uihlein, MD, FCAP, FASCP

    Dr. Arlette Uihlein is Senior Vice President of Regulatory Affairs and Quality for Predictive Oncology and Site Leader of Helomics, serving as the Vice President of Operations, Pathology Services and Medical Director of Helomics® Clinical and Research Labs since 2011. Dr. Uihlein is Board Certified in Anatomic and Clinical Pathology, Cytopathology and Family Medicine. Dr. Uihlein completed her Pathology Residency at Allegheny General Hospital, where she served as Chief Resident in Pathology and completed Fellowships in Cytopathology and Surgical Pathology. During that time, she conducted extensive clinical research involving molecular pathology diagnostic and predictive markers, imaging of solid tumors, and novel applications of cellular tumor markers. While serving as Medical Director at Helomics, a CLIA and New York State certified lab, Dr. Uihlein has published research in molecular assay development, lab automation, and tissue and cell processing. She is a Designated Civil Surgeon for the U.S. Dept. of Justice and a certified Medical Review Officer for the Department of Transportation. She is a Fellow of the College of American Pathologists and the American Society of Clinical Pathology, NYSDOH Certificate Qualified, and a member of ASCO.

    “ At Helomics we’re delivering better-informed decision making saving pharma time and money, while providing cancer patients with appropriate therapies.”

     

     

    Education

    Medical College of Ohio
    Doctor of Medicine

    Baldwin-Wallace University
    BS, Biology

    Richard Gabriel, BS, MBA

    SVP, RESEARCH & DEVELOPMENT
    Predictive Oncology
    Site Leader, TumorGenesis
    At Predictive Oncology
    My role at Predictive Oncology is to bring the business sense to managing Research and Development programs at all our companies. To seek new ways and opportunities to commercialize exciting new technologies that we have built, licensed, acquired, or are developing through our own research and development. The success of any company is to get the research off the bench and to the customers. That is what I do at POAI and help the other companies as well.
    Before Predictive Oncology
    Prior to starting his first company in 1984 and registering with the FDA a pilot plant facility to make pharmaceutical actives, Mr. Gabriel managed a $50 million product line for W.R. Grace, developed new marketing and sales strategies for Ventron a Division of Morton Thiokol, research work at Ashland Chemical for pressure sensitive adhesives and plant scale-up. Since then, he ran a genetics company, built three GMP/Research facilities, and helped 5 drugs reach their markets in AIDS and cancer. Real expertise in cGMP process scale-up and compliance. Completely understand the needs of an API manufacturing facility and build processes that are scalable, environmentally acceptable, and safe. 3 FDA inspections with no 483’s, ISO certification, DEA registration, DoD compliance, NCI contractor and inventor. Has also broad-based experience in start-up companies and how to make them operational and profitable. 7 years of Team set-up, R&D management, and implementation for 165-person (85 PhD’s and Engineers) company (Pharm-Eco) and lecturer on cGMP and Teams within the Pharmaceutical Industry.

    “ Patients are always first, is our driving force. Oncology is a tough space, and we are determined to bring the best validated science to help cancer patients and as our CEO says, ‘Eliminate Cancer.’ That takes teamwork and a lot of smart hard-working people, our team members at POAI are up to the challenge. ”

     

     

    Education
    Suffolk University
    Executive MBA Program

    Ohio Dominican College
    BS, Chemistry

    Ohio State University
    Microbiology and Virology

    University of Cincinnati
    Associates Degree, Liberal Arts

    Mark A Collins, Ph.D

    SCIENTIFIC/CUSTOMER DEVELOPMENT
    Predictive Oncology
    Chief Technical Officer, Helomics
    At Predictive Oncology

    Mark is currently Chief Technical Officer at Predictive Oncology. Using the power of AI, Mark is responsible for leveraging Helomics’ vast repository of physical and digital tumor samples, to build multi-omic predictive models of tumor drug response and outcome. Such models can be applied to the discovery of new targeted therapies for cancer as well as used in clinical decision support to help oncologists individualize  treatment.

    Before Predictive Oncology

    Dr. Mark Collins embarked on a career in the pharmaceutical industry following his postdoctoral work. Pursuing a passion for both biology and computing, Mark has held multiple executive roles in a variety of discovery, informatics and bioinformatics functions within global pharma, and founded three startup software companies in the artificial intelligence (AI) machine learning (ML) and drug discovery space. Mark relocated to the USA in 2001 to work for Cellomics (now part of Thermo Fisher Scientific), where he played a pivotal role in establishing the High-Content cell analysis market, building, and commercializing several key informatics and bioinformatics products.

    Since leaving Thermo Fisher, Mark has focused on developing and commercializing informatics solutions for clinical and translational research, specifically in the specimen tracking, ‘omics data management and NGS analysis space, through key roles at BioFortis, Global Specimen Solutions and Genedata

    “ I have been pursuing a vision since the late 1990s that AI will help deliver better patient therapies. I firmly believe at POAI we will deliver on that vision. ”

    Education
    University of Surrey, UK
    Ph.D., Microbiology

    University of Wolverhampton, UK
    Undergraduate Degree, Applied Science

    Bob Myers, BBA, MBA

    CHIEF FINANCIAL OFFICER
    Predictive Oncology
    Site Leader, Skyline Medical
    At Predictive Oncology

    Executive Officer, Compliance Officer, Corporate Secretary, and member of the Senior Leadership Team. Responsible for Finance, Administration, Human Resources, Investor Relations, and IT. Skyline Medical Site Leader.

    Before Predictive Oncology

    Numerous years as CEO/Controller consultant including medical devices companies. Executive positions with CES Computer Solutions, Computer Accomplishments, Hi-Tech Stationary & Printing, Capital Distributors Corp, International Creative Management American Express, Showtime Entertainment and public accounting with Laventhol & Horwath, CPA’s.

    “ It’s a privilege to work with a highly talented team to pursue oncology advances, while protecting and increasing shareholder value. ”

    Education

    Adelphi University
    MBA, Finance

    Hofstra University
    BBA, Public Accounting 

    J. Melville (“Mel”) Engle, BS, MBA

    CHIEF EXECUTIVE OFFICER
    & CHAIRMAN OF THE BOARD
    Predictive Oncology
    At Predictive Oncology
    Mr. Engle became POAI’s CEO in 2021 and was appointed to the POAI Board of Directors in 2016. He was elected Chairman of the Board in 2020.
    Before Predictive Oncology

    Between 2012 and 2021, he was CEO of Engle Strategic Solutions, a consulting and coaching company focused on CEO issues. From 2009 to 2012, he was CEO and Chairman of Thermogenesis, a cell separation company. From 2002 to 2007, he was Regional Head/Director, North America at Merck Generics and CEO of Dey Laboratories, a respiratory company. From 1996 to 2001, he was CEO and Chairman of Anika Therapeutics, an orthobiologics company. From 1980 to 1995, he was with Allergan, Inc., an eye and skin care company, where he served as CFO, Managing Director (living in Toronto), and other positions with the firm.

    “ Eliminating cancer is our overall goal.  This is not an easy task.  We are working hard every day to make this happen, using our novel technology and talented team of employees. ”

    Education

    University of Southern California
    School of Business
    MBA, Finance

    University of Colorado Boulder
    BS, Accounting